Human platelet antigens (HPA) are polymorphisms in platelet antigens. These can stimulate production of alloantibodies (that is, antibodies against other people's antigens) in recipients of …

2023年6月27日 · 大多数患者可检测出IgG型抗HPA-1a抗体，一般持续存在12～15个月。 因此，输血后紫癜应进行血小板抗体检测，可以明确诊断。 研究发现，抗GPIb抗体阳性的ITP患者对糖 …

Approximately 80% of these antibodies form in neonatal alloimmune thrombocytopenia anti-HPA-1a (PL A1). This same antibody is implicated in cases of post-transfusion purpura, in which the …

2023年7月6日 · Human platelet antigen-1a (HPA-1a) negative platelets are used to treat neonatal alloimmune thrombocytopenia (NAIT), a bleeding disorder in newborns.

Fetal neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against the human platelet antigens (mostly HPA‐1a or HPA‐5b) of the (unborn) child …

2015年6月15日 · Human platelet Ag (HPA)-1a, located on integrin β3, is the main target for alloantibodies responsible for fetal and neonatal alloimmune thrombocytopenia (FNAIT) in the …

研究表明，血小板抗体是影响血小板输注效果的主要免疫因素之一。目前发现与ptr相关的hpa主要是hpa-1b、5a和5b[7]。若患者输注与其本身hpa不相合的血小板，就可能产生hpa抗体，引起 …

2017年4月21日 · We found that human anti-HPA-1a mAb 26.4 partially inhibits adhesion and migratory capacity of HTR8/SVneo cells. Our findings suggest that anti-HPA-1a antibodies …

2017年4月21日 · Results: We found that human anti-HPA-1a mAb 26.4 partially inhibits adhesion and migratory capacity of HTR8/SVneo cells. Conclusions: Our findings suggest that anti-HPA …

An incompatibility between human platelet antigen (HPA)-1a accounts for the majority of FNAIT cases. Binding of HPA-1a-specific alloantibodies to their target on fetal platelets and …